Featured

January 10, 2023

Alto touts new PhIIa depression data with plans to keep charging forward

January 10, 2023

BioTech Nation Interview with Dr. Amit Etkin, Founder & CEO, Alto Neuroscience

October 11, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

January 10, 2023

Alto touts new PhIIa depression data with plans to keep charging forward

January 10, 2023

BioTech Nation Interview with Dr. Amit Etkin, Founder & CEO, Alto Neuroscience

October 11, 2022

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

In the News

New biomarker test accurately predicts who will respond to antidepressant

January 25, 2023

Subscription Required

Alto De-Risks Precision Approach To Psychiatry With Phase IIa Depression Success

January 12, 2023

Alto Neuroscience Announces Positive Phase II Results Supporting Precision Psychiatry Platform

January 11, 2023

Alto’s Biomarker-Based Depression Trial Bears Positive Data

January 11, 2023

BioTech Nation Interview with Dr. Amit Etkin, Founder & CEO, Alto Neuroscience

January 10, 2023

Alto says depression drug shows 'clear' clinical signal in biomarker-defined patients

January 10, 2023

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Receive updates from Alto

Thanks for signing up!

Oops! Something went wrong while submitting the form.

© Alto Neuroscience 2022